Drug Profile
Bendamustine injection - Jiangsu Simcere Pharmaceutical
Alternative Names: Bendamustine hydrochloride injection - SimcereLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Jiangsu Simcere Pharmaceutical; Simcere Pharmaceutical Group
- Developer Jiangsu Simcere Pharmaceutical
- Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
- Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 30 Nov 2018 Discontinued - Preregistration for B-cell lymphoma in China (IV)
- 30 Nov 2018 Discontinued - Preregistration for Chronic lymphocytic leukaemia in China (IV)
- 01 Aug 2013 Simcere completes a phase II trial in Chronic lymphocytic leukaemia (treatment naive) in China (NCT01109264)